Squarepoint Ops LLC Autolus Therapeutics PLC Transaction History

Squarepoint Ops LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.33 - $5.68 $68,561 - $116,945	20,589 New	20,589 $71,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $18,108 - $34,030	10,407 New	10,407 $19,000
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $394,837 - $657,511	-82,602 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $453,484 - $773,154	82,602 New	82,602 $473,000
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $349,409 - $489,293	-30,018 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.38 - $16.14 $79,204 - $237,613	14,722 Added 96.25%	30,018 $481,000
Q1 2020 May 15, 2020	BUY	$4.2 - $13.0 $64,243 - $198,848	15,296 New	15,296 $92,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.